Commonly used nonablative or reduced toxicity regimens.

Nonablative regimens do not eradicate host hematopoiesis and immunity, and autologous recovery occurs if the graft is rejected. Many regimens proposed to reduce toxicity still require transplantation to be safely administered, and graft rejection results in prolonged pancytopenia; these regimens should be considered reduced toxicity ablative regimens. Increased intensity of immunosuppression is necessary for engraftment of unrelated donor or haploidentical transplants.

Abbreviations: Flag-ida, fludarabine, cytosine arabinoside, idarubicin; FC, fludarabine cyclophosphamide; MF, melphalan-fludarabine; TBI, total body radiation; F-TBI, fludarabine-TBI; TT-C, thiotepa-cyclophosphamide; TT-M-ATG, thiotepa-melphalan-antithymocyte globulin; BU, busulfan; CY, cyclophosphamide; Haplo T Cell Dep, haploidentical T cell depleted, MUD, matched unrelated donor.